外科理论与实践››2022,Vol. 27››Issue (06): 495-499.doi:10.16139/j.1007-9610.2022.06.03
李成鹏, 郝纯毅(
)
收稿日期:2022-09-26出版日期:2022-11-25发布日期:2023-01-30通讯作者:郝纯毅，E-mail:
LI Chengpeng, HAO Chunyi()
Received:2022-09-26Online:2022-11-25Published:2023-01-30| [1] | Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine[J]. CA Cancer J Clin, 2020, 70(3):200-229. doi:10.3322/caac.21605URL |
| [2] | Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution[J]. Ann Surg, 1998, 228(3):355-365. doi:10.1097/00000658-199809000-00008pmid:9742918 |
| [3] | Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients[J]. J Clin Oncol, 2009, 27(1):24-30. doi:10.1200/JCO.2008.17.8871pmid:19047283 |
| [4] | Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control[J]. J Clin Oncol, 2009, 27(1):31-37. doi:10.1200/JCO.2008.18.0802pmid:19047280 |
| [5] | Milne I. Who was James Lind, and what exactly did he achieve[J]. J R Soc Med, 2012, 105(12):503-508. doi:10.1258/jrsm.2012.12k090URL |
| [6] | Raistrick H, Scadding JG, Tytler WH, et al. Streptomycin treatment of pulmonary tuberculosis[J]. Br Med J, 1948, 2(4582):769-782. |
| [7] | Ergina PL, Cook JA, Blazeby JM, et al. Challenges in evaluating surgical innovation[J]. Lancet, 2009, 374(9695):1097-1104. doi:10.1016/S0140-6736(09)61086-2pmid:19782875 |
| [8] | Barkun JS, Aronson JK, Feldman LS, et al. Evaluation and stages of surgical innovations[J]. Lancet, 2009, 374(9695):1089-1096. doi:10.1016/S0140-6736(09)61083-7pmid:19782874 |
| [9] | The Lancet. Surgical research: the reality and the IDEAL[J]. Lancet, 2009, 374(9695):1037. doi:10.1016/S0140-6736(09)61678-0pmid:19782850 |
| [10] | Strauss DC. Patterns of recurrence in retroperitoneal liposarcomas: reflecting surgical approach or tumor biology?[J]. Ann Surg Oncol, 2014, 21(7):2113-2116. doi:10.1245/s10434-014-3644-3pmid:24647676 |
| [11] | Hartgritik HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? final results of the randomized Dutch Gastric Cancer group trial[J]. J Clin Oncol, 2004, 22(11):2069-2077. doi:10.1200/JCO.2004.08.026pmid:15082726 |
| [12] | Songun I, Putter H, Kranenbarg EMK, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5):439-449. doi:10.1016/S1470-2045(10)70070-Xpmid:20409751 |
| [13] | Tseng WW, Tsao-Wei DD, Callegaro D, et al. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma[J]. Eur J Surg Oncol, 2018, 44(6):810-815. doi:S0748-7983(18)30123-9pmid:29452860 |
| [14] | Wang Z, Wu J, Lv A, et al. Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: novel evidence for extended surgery and a tumor grading system[J]. Biosci Trends, 2018, 12(2):185-192. doi:10.5582/bst.2018.01015pmid:29657244 |
| [15] | Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgeryversussurgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(10):1366-1377. doi:S1470-2045(20)30446-0pmid:32941794 |
| [16] | van Houdt WJ, Raut CP, Bonvalot S, et al. New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration[J]. Curr Opin Oncol, 2019, 31(4):310-316. doi:10.1097/CCO.0000000000000535pmid:30893150 |
| [17] | Dickson MA, Tap WD, Keohan ML, et al. Phase Ⅱ trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma[J]. J Clin Oncol, 2013, 31(16):2024-2028. doi:10.1200/JCO.2012.46.5476pmid:23569312 |
| [18] | Bill KL, Garnett J, Meaux I, et al. SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma[J]. Clin Cancer Res, 2016, 22(5):1150-1160. doi:10.1158/1078-0432.CCR-15-1522pmid:26475335 |
| [19] | Gounder MM, Razak AA, Somaiah N, et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial[J]. J Clin Oncol, 2022, 40(22):2479-2490. doi:10.1200/JCO.21.01829URL |
| [1] | 刘文帅, 陆维祺, 周宇红.腹膜后肉瘤诊疗规范、难点和发展方向——CSCO指南解读[J]. 外科理论与实践, 2022, 27(06): 483-489. |
| [2] | 陈骏, 罗成华.腹膜后肿瘤外科发展的历史、现状与前景展望[J]. 外科理论与实践, 2022, 27(06): 490-494. |
| [3] | 邱法波, 周斌, 曲腾飞.腹膜后肿瘤外科的规范及手术质量控制[J]. 外科理论与实践, 2022, 27(06): 526-529. |
| [4] | 潘向欧, 张莉, 侯佳舟, 杜世锁, 曾昭冲, 王斌梁.切除困难或不可切除原发性腹膜后软组织肉瘤术前转化放射治疗的研究[J]. 外科理论与实践, 2022, 27(06): 530-533. |
| [5] | 庄奥博, 童汉兴, 张勇, 陆维祺, 周宇红, 闾晨涛.老年原发性腹膜后软组织肉瘤病人手术治疗安全性分析的回顾性队列研究[J]. 外科理论与实践, 2022, 27(06): 534-539. |
| [6] | 秦昌富, 李炳根, 申英末, 陈杰.中国疝病注册登记随访系统的建立和发展[J]. 外科理论与实践, 2018, 23(04): 295-298. |
| [7] | 郑良荣,.经皮左心耳封堵术在心房颤动卒中预防中的临床研究进展[J]. 内科理论与实践, 2018, 13(01): 10-14. |
| [8] | 殷浩, 傅志仁,.血型不相容肝移植的临床研究进展[J]. 外科理论与实践, 2014, 19(04): 296-300. |
| [9] | 纪元, 杜敏,.软组织肉瘤的分子分型及其临床意义[J]. 外科理论与实践, 2012, 17(04): 390-393. |
| [10] | 侯英勇,.腹部软组织肉瘤的分期分级与治疗的相关意义[J]. 外科理论与实践, 2012, 17(04): 314-316. |
| [11] | 赵如平, 姚伟强, 郭小毛,.腹膜后软组织肉瘤放疗现状及研究进展[J]. 外科理论与实践, 2012, 17(04): 386-389. |
| [12] | 师英强,.重视腹腔及腹膜后肉瘤的诊治[J]. 外科理论与实践, 2012, 17(04): 297-300. |
| [13] | 韩毓, 柴宇啸, 王奕静, 张怡, 曲兴龙,.隆突性皮肤纤维肉瘤的诊断和治疗(附22例报告)[J]. 外科理论与实践, 2010, 15(02): 173-174. |
| [14] | 汪谦,.临床科研的选题与相关社会科学问题[J]. 外科理论与实践, 2010, 15(01): 1-2. |
| [15] | 杨娴娴，穆雄铮.颅颌面牵引成骨术的临床应用[J]. 组织工程与重建外科杂志, 2009, 5(6): 301-317. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
